ADVERTISEMENT

AACR 2022 — A novel natural killer cell-based immunotherapy for CD30+ relapsed/refractory lymphomas

Elena Riboldi — Agenzia Zoe   |   Conference Report   |   14 April 2022
ADVERTISEMENT

Takeaway

  • In patients with CD30+ relapsed/refractory lymphomas, infusions of preactivated cord blood (CB)-derived natural killer (NK) cells complexed with AFM13, a bispecific antibody that binds CD16A on NK cells and CD30 on lymphoma cells, are safe.
  • The approach showed early efficacy and warrants further investigation.

Why this matters

  • CB-derived NK...

          

March Challenge

Ends in 11d 14h
left
right

Topic Challenges

left
right